Patents by Inventor Nabil Abraham

Nabil Abraham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10792332
    Abstract: As microbial drug-resistance increases, there is a critical need for new classes of compounds to combat infectious diseases. The Ixodes scapularis tick antifreeze glycoprotein, IAFGP, functions as an anti-infective agent against diverse bacteria including methicillin-resistant Staphylococcus aureus. Recombinant IAFGP and a peptide, P1, described herein and derived from this protein, bind to microbes and alter biofilm formation. Transgenic iafgp-expressing flies and mice challenged with bacteria, as well as wild-type animals administered IAFGP or P1, were resistant to infection, septic shock, or biofilm development on implanted biomaterials. Antifreeze protein controls bacterial infection and present new therapeutic strategies to counter pathogens.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: October 6, 2020
    Assignees: Yale University, Howard Hughes Medical Institute
    Inventors: Erol Fikrig, Martin Heisig, Nabil Abraham, Girish Neelakanta
  • Publication number: 20190125831
    Abstract: As microbial drug-resistance increases, there is a critical need for new classes of compounds to combat infectious diseases. The Ixodes scapularis tick antifreeze glycoprotein, IAFGP, functions as an anti-infective agent against diverse bacteria including methicillin-resistant Staphylococcus aureus. Recombinant IAFGP and a peptide, P1, described herein and derived from this protein, bind to microbes and alter biofilm formation. Transgenic iafgp-expressing flies and mice challenged with bacteria, as well as wild-type animals administered IAFGP or P1, were resistant to infection, septic shock, or biofilm development on implanted biomaterials. Antifreeze protein controls bacterial infection and present new therapeutic strategies to counter pathogens.
    Type: Application
    Filed: September 6, 2018
    Publication date: May 2, 2019
    Applicants: Yale University, Howard Hughes Medical Institute
    Inventors: Erol Fikrig, Martin Heisig, Nabil Abraham, Girish Neelakanta
  • Patent number: 10092626
    Abstract: As microbial drug-resistance increases, there is a critical need for new classes of compounds to combat infectious diseases. The Ixodes scapularis tick antifreeze glycoprotein, IAFGP, functions as an anti-infective agent against diverse bacteria including methicillin-resistant Staphylococcus aureus. Recombinant IAFGP and a peptide, PI, described herein and derived from this protein, bind to microbes and alter biofilm formation. Transgenic iafgp-expressing flies and mice challenged with bacteria, as well as wild-type animals administered IAFGP or PI, were resistant to infection, septic shock, or biofilm development on implanted biomaterials. Antifreeze protein controls bacterial infection and present new therapeutic strategies to counter pathogens.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: October 9, 2018
    Assignees: Yale University, Howard Hughes Medical Institute
    Inventors: Erol Fikrig, Martin Heisig, Nabil Abraham, Girish Neelakanta
  • Publication number: 20160317618
    Abstract: As microbial drug-resistance increases, there is a critical need for new classes of compounds to combat infectious diseases. The Ixodes scapularis tick antifreeze glycoprotein, IAFGP, functions as an anti-infective agent against diverse bacteria including methicillin-resistant Staphylococcus aureus. Recombinant IAFGP and a peptide, PI, described herein and derived from this protein, bind to microbes and alter biofilm formation. Transgenic iafgp-expressing flies and mice challenged with bacteria, as well as wild-type animals administered IAFGP or PI, were resistant to infection, septic shock, or biofilm development on implanted biomaterials. Antifreeze protein controls bacterial infection and present new therapeutic strategies to counter pathogens.
    Type: Application
    Filed: December 17, 2014
    Publication date: November 3, 2016
    Applicant: Yale University
    Inventors: Erol Fikrig, Martin Heisig, Nabil Abraham, Girish Neelakanta